Document is current

Article History

Received: 5 January 2025

Revised: 16 February 2025

Accepted: 1 March 2025

First Online: 26 March 2025

Declarations

:

: SL and DE have nothing to disclose. AK has received a study grant from Novartis. AS has no personal pecuniary interests to disclose, other than being the lead of the German MS Registry, which receives (project) funding from a range of public and corporate sponsors, recently including The German Ministry The German Innovation Fund (G-BA), The German Retirement Insurance, The German MS Trust, The German MS Society, Biogen GmbH, BristolMyersSquibb, Merck Healthcare Germany GmbH, Novartis Pharma GmbH, Roche Pharma AG, and TG Therapeutics. PSR has received speaking fees, honoraria from advisory boards, and/or financial support for research activities from A-Med, Alexion/AstraZeneca, Almirall, AMGEN, Amicus, Biogen, Merck, neuraxpharm, Novartis, Roche, Sandoz, Sanofi, and Teva. JH serves as president of the German MS Society, federal association, which receives funding from a range of public and corporate sponsors, recently including BMG, G-BA, The German MS Trust, Biogen, BMS, Merck Serono, Novartis, Roche, Sanofi, and Viatris. CW has received institutional support from Novartis, Alexion, Sanofi Genzyme, Biogen, Merck, Janssen, Bayer, and Roche. He has received personal honoraria for teaching lectures from Biontech, Medpoint Medizinkommunikations, F&U confirm, Privatinstitut für Klinikmanagement, and The Royal College Of Physicians, and for consulting from Wuesthoff + Wuesthoff and Bristows LLP.

: The registration of the GMSR proceeded at the German Registry for Clinical Trials (Deutsches Register Klinischer Studien [DRKS]; No. DRKS00011257). The initial ethics vote was approved by University of Würzburg’s institutional review board (permit No. 142/12).